Exploratory analysis of front-line therapies in REVEL

• Verfasst von: Garon, Edward B. [VerfasserIn]
• Verfasst von: Scagliotti, Giorgio Vittorio [VerfasserIn]
• Verfasst von: Gautschi, Oliver [VerfasserIn]
• Verfasst von: Reck, Martin [VerfasserIn]
• Verfasst von: Thomas, Michael [VerfasserIn]
• Verfasst von: Docampo, Lara Iglesias [VerfasserIn]
• Verfasst von: Kalofonos, Haralabos [VerfasserIn]
• Verfasst von: Kim, Joo-Hang [VerfasserIn]
• Verfasst von: Gans, Steven [VerfasserIn]
• Verfasst von: Brustugun, Odd Terje [VerfasserIn]
• Verfasst von: Orlov, Sergey V. [VerfasserIn]
• Verfasst von: Carter, Gebra Cuyun [VerfasserIn]
• Verfasst von: Zimmermann, Annamaria H. [VerfasserIn]
• Verfasst von: Oton, Ana B. [VerfasserIn]
• Verfasst von: Alexandris, Ekaterine [VerfasserIn]
• Verfasst von: Lee, Pablo [VerfasserIn]
• Verfasst von: Wolff, Katharina [VerfasserIn]
• Verfasst von: Stefaniak, Victoria Jennifer [VerfasserIn]
• Verfasst von: Socinski, Mark A. [VerfasserIn]
• Verfasst von: Pérol, Maurice [VerfasserIn]
• Titel: Exploratory analysis of front-line therapies in REVEL
• Titelzusatz: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy
• Verf.angabe: Edward B. Garon, Giorgio Vittorio Scagliotti, Oliver Gautschi, Martin Reck, Michael Thomas, Lara Iglesias Docampo, Haralabos Kalofonos, Joo-Hang Kim, Steven Gans, Odd Terje Brustugun, Sergey V. Orlov, Gebra Cuyun Carter, Annamaria H. Zimmermann, Ana B. Oton, Ekaterine Alexandris, Pablo Lee, Katharina Wolff, Victoria Jennifer Stefaniak, Mark A. Socinski, Maurice Pérol
• Jahr: 2020
• Jahr des Originals: 2019
• Fussnoten: Gesehen am 18.05.2020
• Titel Quelle: Enthalten in: ESMO open
• Ort Quelle: London : BMJ, 2015
• Jahr Quelle: 2020
• Band/Heft Quelle: 5(2020,1) Artikel-Nummer e000567, 11 Seiten
• ISSN Quelle: 2059-7029
• DOI: doi:10.1136/esmoopen-2019-000567
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: chemotherapy
• Sach-SW: metastatic
• Sach-SW: non-squamous
• Sach-SW: squamous
• Sach-SW: vascular endothelial growth factor receptor
• K10plus-PPN: 169845015X

Abstract

Introduction Non-small-cell lung cancer (NSCLC) is a heterogeneous disease. Front-line therapy may affect responses to subsequent treatment regimens, thus influencing second-line therapy decision making. In the randomised phase 3 REVEL study, second-line ramucirumab plus docetaxel (ram+doc) versus docetaxel (doc) improved survival of patients with metastatic NSCLC. We explore efficacy, safety and quality-of-life (QoL) in REVEL based on front-line therapy. - Methods Patients were grouped by specific front-line therapy received. Overall survival (OS), progression-free survival (PFS), objective response rate, safety and QoL were assessed descriptively. Kaplan-Meier estimation and Cox proportional hazards modelling were used; frequencies reported in percentages. - Results Baseline characteristics of 1253 patients were generally well balanced between treatment arms within each front-line therapy subgroup. For patients with non-squamous disease (n=912), induction therapies included platinum-based chemotherapy plus a taxane (n=227; 25%) or pemetrexed (n=449; 49%), with (n=172; 19%) or without bevacizumab. For patients with squamous disease (n=328), induction therapies included platinum-based chemotherapy plus gemcitabine (n=176; 54%) or a taxane (n=69; 21%). A highly selected subgroup (n=127; 14%) received pemetrexed continuation maintenance therapy. Ram+doc improved median OS and PFS versus doc across front-line therapy subgroups, as reflected by HRs ranging from 0.78 to 0.91 and 0.66 to 0.92, respectively, similar to results in the overall intention-to-treat cohort (HRs: 0.86 and 0.76, respectively). High-grade treatment-emergent adverse events of special interest (including neutropenia, febrile neutropenia, leucopenia and hypertension) were generally higher in ram+doc-treated patients relative to doc-treated patients regardless of front-line therapy. No clear differences in safety or QoL were seen across front-line therapy subgroups; outcomes were consistent with those reported in the overall intention-to-treat cohort. - Conclusions Results of this exploratory analysis suggest that second-line ram+doc may be effective regardless of prior treatment with platinum-based chemotherapy plus a taxane, pemetrexed, gemcitabine or bevacizumab. Overall, ram+doc is clinically beneficial across a wide range of patients with metastatic NSCLC who have progressed after various front-line therapies. - Trial registration number NCT01168973.